CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 626 enrolled
Drug / intervention
FCM (Ferric carboxymaltose) high ferritin target +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00994318
NCT00994318Phase 3Completed

An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease

Vifor Pharma·interventional·Posted Oct 14, 2009·Updated May 20, 2014

In Brief

A Phase 3 clinical trial evaluating FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, and 1 other intervention for Iron Deficiency Anaemia and Chronic Kidney Disease. Completed, enrolled 626 participants across 19 sites in 19 countries.

Detailed Summary

Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 14, 2009
Enrollment StartDec 1, 2009
Primary CompletionFeb 1, 2013
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 16.7 years ago

Interventions

FCM (Ferric carboxymaltose) high ferritin targetdrug

FCM (Ferric carboxymaltose) low ferritin targetdrug

Oral Iron (Ferrous sulphate)drug